度普利尤治疗顽固性结节性痒疹3例

Dupilumab in the Treatment of Refractory Prurigo Nodularis:Three Case Reports

结节性痒疹(prurigo nodularis,PN)是一种以躯干、四肢起结节伴剧烈瘙痒的慢性炎症性皮肤病,多见于女性,结节好发于双下肢。该病发病机制尚不明确,主要涉及2型炎症反应。度普利尤单抗注射液为靶向白细胞介素-4受体亚基α(IL-4R-α)的全人单克隆抗体(IgG4型),能选择性抑制IL-4/IL-13信号传导,从而抑制2型炎症反应。本文报道的3例PN患者经度普利尤治疗后均取得了显著疗效。

Prurigo nodularis(PN)is a chronic inflammatory skin disease with nodules on the trunk and limbs accompanied by severe itching,which is more common in female patients,and the nodules are more common in both lower limbs,and its pathogenesis is still unclear,mainly involving type 2 inflammatory reaction.Dupilumab injection is a fully human monoclonal antibody(IgG4 type)targeting the interleukin-4 receptor subunit α(IL-4R-α),which can selectively inhibit IL-4/IL-13 signaling,thereby inhibiting type 2 inflammatory response.The three PN patients reported in this article achieved significant eficacy after treatment with Dupriyu combined.